entocort cr 3mg capsules
dowelhurst ltd - budesonide - modified-release capsule - 3mg
clindamycin 150mg capsules
kent pharma (uk) ltd - clindamycin hydrochloride - oral capsule - 150mg
entocort cr 3mg capsules
de pharmaceuticals - budesonide - modified-release capsule - 3mg
cozaar 2.5mg/ml oral suspension
organon pharma (uk) ltd - losartan potassium - oral suspension - 2.5mg/1ml
ramipril 10mg capsules
de pharmaceuticals - ramipril - oral capsule - 10mg
zenpep- pancrelipase lipase, pancrelipase protease, pancrelipase amylase capsule, delayed release
allergan, inc. - pancrelipase lipase (unii: 8myc33932o) (pancrelipase lipase - unii:8myc33932o), pancrelipase protease (unii: 3560d81v50) (pancrelipase protease - unii:3560d81v50), pancrelipase amylase (unii: yoj58o116e) (pancrelipase amylase - unii:yoj58o116e) - pancrelipase lipase 3000 [usp'u] - zenpep® is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. none. risk summary published data from case reports with pancrelipase use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. pancrelipase is minimally absorbed systematically; therefore, maternal use is not expected to result in fetal exposure to the drug. animal reproduction studies have not been conducted with pancrelipase. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary there are no data on the presence of pancrelipase in either human or animal milk, the effects
zentel 400mg tablets
glaxosmithkline south africa ltd. - albendazole - tablets - 400mg
nurofen advance 200mg tablets
reckitt benckiser ireland ltd - ibuprofen lysinate - film-coated tablet - 200 milligram(s) - propionic acid derivatives; ibuprofen
teglutik riluzole 50 mg/10 ml oral liquid suspension bottle
seqirus pty ltd - riluzole, quantity: 0.5 g - oral liquid, suspension - excipient ingredients: sorbitol solution (70 per cent) (non-crystallising); aluminium magnesium silicate; xanthan gum; saccharin sodium; sodium lauryl sulfate; ceteareth-25; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate - riluzole is indicated for the treatment of patients with amyotrophic lateral sclerosis (als).
tramadol 50mg capsules
relonchem ltd - tramadol hydrochloride - oral capsule - 50mg